简介：AIM:Toassessthevalueofgemstonespectralimaging(GSI)inefficacyevaluationinhepatocellularcancer(HCC)aftertranscatheterarterialchemoembolization(TACE)treatment.METHODS:ThirtypatientswithHCCunderwentGSI,includingnonenhanced,arterial,portalvenousanddelayedphasescans,afterTACEtreatment.ArterialphaseimageswereacquiredwithGSIforreconstructionofvirtualnonenhancedimagesandcoloroverlayimages.Digitalsubtractionangiography(DSA)wasperformedinallthesepatients.Twoblindedandindependentreadersevaluatedthedataintworeadingsessions;standardnonenhanced,arterial,portalvenous,anddelayedphaseimageswerereadinsessionA,andtheoptimalmonochromaticimages,iodine/waterbasedimagesandspectrumfeatureswerereadinsessionB.SensitivityandspecificitywerecalculatedwiththeDSAdataasthereferencestandard.Thesensitivityandspecificitywerecomparedusingtheχ2test.RESULTS:DSArevealed154lesionsin30patients,and100ofthemhadbloodsupply.Overallsensitivityandspecificitywere72%(72/100)and77.8%(42/54)forsessionA,and97%(97/100)and94.4%(51/54)forsessionB,respectively.Thesensitivityandspecificityofthetworeadingsessionsweresignificantlydifferent(χ2=23.04,χ2=7.11,P<0.05).CONCLUSION:ComparedwithconventionalCT,GSIcouldsignificantlyimprovethedetectionofsmallandmultiplelesionswithoutincreasingtheradiationdose.Basedonspectrumfeatures,GSIcouldassesstumorhomogeneityandmoreaccuratelyidentifyresidualtumorsandrecurrentormetastaticlesionsduringefficacyevaluationandfollow-upinHCCafterTACEtreatment.

简介：AIMToevaluatetheclinicaloutcomesofpatientswhounderwentendoscopicsubmucosaltunneldissection(ESTD)foresophagealsquamouscellcarcinoma(ESCC)andprecancerouslesions.METHODSESTDwasperformedin289patients.Theclinicaloutcomesofthepatientsandpathologicalfeaturesofthelesionswereretrospectivelyreviewed.RESULTSAtotalof311lesionswereincludedintheanalysis.Theenblocrate,completeresectionrate,andcurativeresectionratewere99.04%,81.28%,and78.46%,respectively.TheESTDproceduretimewas102.4±35.1min,themeanhospitalizationtimewas10.3±2.8d,andtheaverageexpenditurewas3766.5±846.5dollars.Theintraoperativebleedingratewas6.43%,thepostoperativebleedingratewas1.61%,theperforationratewas1.93%,andthepostoperativeinfectionratewas9.65%.Esophagealstrictureandpositivemarginweresevereadverseevents,withanincidencerateof14.79%and15.76%,respectively.Notumorrecurrenceoccurredduringthefollow-upperiod.CONCLUSIONESTDforESCCandprecancerouslesionsisfeasibleandrelativelysafe,butforlargemucosallesions,therateofesophagealstrictureandpositivemarginishigh.

简介：AIM:Toinvestigatetheantitumoractivityofadriamycin(ADR)encapsulatedinnanoparticles(NADR)andinjectedintothehepaticarteryofhepatoma-bearingrats.METHODS:NADRwaspreparedbytheinterfacialpolymerizationmethod.Walker-256carcinosarcomasweresurgicallyimplantedintotheleftliverlobesof60maleWistarrats,whichweredividedinto4groupsatrandom(15ratspergroup).Onthe7thdayafterimplantation,normalsaline(NS),freeADR(FADR),NADR,orADRmixedwithunloadednanoparticles(ADR+NP)wasrespectivelyinjectedviathehepaticartery(i.a.)ofratsindifferentgroups.ThedoseofADRineachformulationwas2.0mg/kgbodyweightandtheconcentrationwas1.0mg/mL.Survivaltime,tumorenlargementratio,andtumornecrosisdegreewerecomparedbetweeneachgroup.RESULTS:ComparedwiththeratsthatreceivedNSi.a.,theratsthatreceivedFADRorADR+NPacquiredapparentinhibitionontumorgrowth,aswellasprolongedtheirlifespan.Furthersignificantanticancerefficacywasobservedinratsthatreceivedi.a.administrationofNADR.StatisticsindicatedthatNADRbroughtonamoresignificanttumorinhibitionandmoreextensivetumornecrosis,ascomparedtoFADRorADR+NP.Themeantumorenlargementratioonthe7thdayafterNADRi.a.was1.106.Themeantumorbearingsurvivaltimewas39.50days.Prolongedlifespanratiowas109.22%ascomparedwithratsthatacceptedNS.CONCLUSION:TherapeuticeffectofADRonlivermalignancycanbesignificantlyenhancedbyitsnanopaticleformulationandadministrationviahepaticartery.

简介：AIM:Toevaluatetheefficacyofthe14-dmoxifloxacinbasedtripletherapyforthesecond-lineeradicationofHelicobacterpylori(H.pylori)infection.METHODS:Between2011and2013,weconductedaretrospectivereviewofthemedicalrecordsof160patientswhohadexperiencedfailureoftheirfirst-lineprotonpumpinhibitor-basederadicationtherapyandsubsequentlyreceivedthemoxifloxacin-basedtripletherapyasasecond-lineeradicationtreatmentregimen.Thepatientswhoweretreatedwiththemoxifloxacinbasedtripletherapy(oral20mgrabeprazoleb.i.d.,1000mgamoxicillinb.i.d.,and400mgmoxifloxacinq.d.)for7dwereassignedtotheRAM-7group(n=79)whilethosewhotookthemfor14dayswereassignedtoRAM-14group(n=81).Theeradicationratesforbothgroupsweredeterminedbyintentionto-treat(ITT)andper-protocol(PP)analyses.ITTanalysiscomparedthetreatmentgroupsasoriginallyallocatedwhilethePPanalysisincludingonlythosepatientswhohadcompletedthetreatmentasoriginallyallocated.SuccessfuleradicationtherapyforH.pyloriinfectionwasdefinedasthedocumentationofanegative13C-ureabreathtest4wkaftertheendoftheeradicationtreatment.RESULTS:TheoverallITTeradicationratewas76.2%(122/160).ThefinalITTeradicationrateswere70.8%(56/79;95%CI:63.3%-77.1%)intheRAM-7groupand81.4%(66/81;95%CI:74.6%-88.3%)intheRAM-14group(P=0.034).TheoverallPPeradicationratewas84.1%(122/145),andthefinalPPeradicationrateswere77.7%(56/72;95%CI:70.2%-85.3%)intheRAM-7groupand90.4%(66/73;95%CI:82.8%-98.1%)intheRAM-14group(P=0.017).TheH.pylori-eradicationratesintheRAM-14groupweresignificantlyhighercomparedwiththatoftheRAM-7groupaccordingtoboththeITT(P=0.034)andthePPanalyses(P=0.017).Bothgroupsexhibitedgoodtreatmentcompliance(RAM-7/RAM-14group:100%/100%).Theadverseeventrateswere19.4%(14/72)and20.5%(15/73)intheRAM-7andRAM-14groups,respectively(P=0.441).Adverseeventsoccurredin14